11. Biotech NetWorkshop

28. – 29. June 2017, Munich

PRI-002

Priavoid has successfully applied to start a Phase I clinical trial with PRI-002, a drug for the causal treatment of Alzheimer’s disease. A Phase II clinical trial is in preparation and is scheduled to start in 2018.

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help.

Select an option to continue

Your selection was saved!

Help

Help

To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set.

You can change your cookie setting here anytime: Privacy Policy. Legal Notice

Back